About-cancer/treatment/clinical-trials/disease/skin-cancer/treatment

Lapaʻau i nā hoʻokolohua hoʻokolohua no ka maʻi ʻaʻai non-Melanoma

ʻO nā hoʻokolohua hoʻokolohua kahi noiʻi noiʻi e pili ana i ka poʻe. ʻO nā hoʻokolohua hoʻokolohua ma kēia papa inoa no ka mālama maʻi maʻi ʻili non-melanoma. Kākoʻo ʻia nā hoʻokolohua āpau ma ka papa inoa e NCI.

ʻO ka ʻike pili o NCI e pili ana i nā hoʻokolohua hoʻokolohua e wehewehe i nā ʻano a me nā pae o nā hoʻokolohua a pehea e lawe ai. Nānā nā hoʻāʻo hoʻokolohua i nā ala hou e pale ai, ʻike ai, a mālama ai paha i ka maʻi. E makemake paha ʻoe e noʻonoʻo e pili ana i ka lawe ʻana i ka hoʻokolokolo hoʻokolohua. E kamaʻilio me kāu kauka no ke kōkua i ka hoʻoholo ʻana inā kūpono kekahi iā ʻoe.

Nā hoʻāʻo 1-25 o 118 1 2 3 4 5 Aʻe>

Hoʻonohonoho ʻia ka Therapy Therapy e alakaʻi ʻia e ka genetic Testing i ka mālama ʻana i nā mea maʻi me nā Tumors Refractory Solid Advanced, Lymphomas, a i ʻole Myeloma Multiple (The MATCH Screening Trial)

Ke nānā nei kēia pae II MATCH hoʻokolohua i ka maikaʻi o ke olakino e kuhikuhi ʻia e ka hoʻāʻo genetic i nā mea maʻi me nā tumors paʻa a i ʻole nā ​​lymphomas i holomua ma hope o hoʻokahi laina o ka maʻamau maʻamau a i ʻole ʻaelike i kū ai ke ʻano lapaʻau. Nānā nā hoʻāʻo genetic i nā mea kūlohelohe (genes) o nā hunaola tumula o nā maʻi. ʻO nā mea maʻi me nā ʻano kūlohelohe (e like me ka hoʻololi ʻana, nā hoʻonui ʻana, a i ʻole nā ​​translocations) ke ʻoi aku ka pōmaikaʻi mai ka hoʻomaʻamaʻa e kuhikuhi ana i nā kūlohelohe o kā lākou tumo. ʻO ka hoʻomaopopo ʻana i kēia mau ʻano kūlohelohe e kōkua mua paha i nā kauka e hoʻomaʻamaʻa maikaʻi aʻe no nā mea maʻi me nā tumors paʻa, lymphomas, a i ʻole myeloma he nui.

Kahi: 1189 mau wahi

ʻO Nivolumab ma hope o ka hoʻohui ʻia ʻana o ka pono maʻamau i ka mālama ʻana i nā mea maʻi me ke kūlana kiʻekiʻe kiʻekiʻe II-IIIB ʻAe ʻAkā

Ke nānā nei kēia mahele II i ka hoʻokolohua hoʻokolohua hoʻokolohua pehea ka maikaʻi o ka nivolumab ma hope o ka hoʻoliʻiliʻi modality therapy i ka mālama ʻana i nā mea maʻi me ka maʻi maʻi maʻi maʻi maʻi II-IIIB kiʻekiʻe. Immunotherapy me nā monoclonal antibodies, e like me ka nivolumab, hiki ke kōkua i ke kino ʻōnaehana pale kaua i ka maʻi ʻaʻai, a ke hoʻopilikia paha i ka hiki i nā pūpū tumora ke ulu a pālahalaha.

Kahi: 745 mau wahi

Hoʻohālikelike ʻia ʻo Pembrolizumab i ka nānā ʻana o ka mālama ʻana i ka mālama ʻana i nā mea maʻi me ka pae I-III Merkel Cell cancer i ʻike ʻia.

Ke aʻo nei kēia mahele hoʻokolohua III i ka maikaʻi o ka hana ʻana o ka pembrolizumab i ka maʻamau o ka nānā ʻana i ka mālama ʻana i nā mea maʻi me ka I-III Merkel cell cancer i hoʻopau loa ʻia e ke ʻoki (resected). Immunotherapy me nā monoclonal antibodies, e like me pembrolizumab, hiki ke kōkua i ke kino ʻōnaehana pale kaua i ka maʻi ʻaʻai, a hiki ke hoʻopilikia i ka hiki o nā tumele keola e ulu a pālahalaha aku.

Kahi: 286 mau wahi

ʻO Avelumab me a i ʻole Cetuximab i ka mālama ʻana i nā mea maʻi me ka maʻi ʻaʻai maʻi maʻi holomua

Ke aʻo nei kēia mahele II i ka maikaʻi o ka avelumab me a i ʻole ʻo cetuximab e hana ai i ka mālama ʻana i nā mea maʻi me ka maʻi ʻaʻai squamous cell i pāhola ʻia i nā wahi ʻē aʻe o ke kino (holomua). Hiki paha i ka Immunotherapy me nā antibodies monoclonal, e like me avelumab a me cetuximab, ke kōkua i ke kino pale o ke kino e hoʻouka i ka maʻi ʻaʻai, a e hoʻopilikia paha i ka hiki ke ulu a pālahalaha nā pūnaewele tumora.

Kahi: 277 mau wahi

Pembrolizumab me a i ʻole a i ʻole Stereotactic Kino Radiation Therapy i ka mālama ʻana i nā mea maʻi me ka maʻi ʻaʻai ʻo Advanced a Metastatic Merkel Cell.

Ke aʻo nei kēia mahele II i ka hoʻokolohua ʻana i ka maikaʻi o ka pembrolizumab me a i ʻole me ka ʻole o ke stereotactic body radiation therapy e hana ai i ka mālama ʻana i nā mea maʻi me ka maʻi ʻaʻai Merkel i pāhola ʻia i nā wahi ʻē aʻe o ke kino. Immunotherapy me nā monoclonal antibodies, e like me pembrolizumab, hiki ke kōkua i ke kino ʻōnaehana pale kaua i ka maʻi ʻaʻai, a hiki ke hoʻopilikia i ka hiki o nā tumele keola e ulu a pālahalaha aku. Hoʻohana ka radiation radiation body Stereotactic i nā pono hana kūikawā e hoʻonohonoho i kahi mea maʻi a hāʻawi i ka radiation i nā tumors me ke kiʻekiʻe kiʻekiʻe. Hiki i kēia hana ke luku i nā hunaola puʻupuʻu me ka liʻiliʻi o nā mahele ma kahi o ka manawa pōkole a hōʻemi i ka hōʻino ʻana i nā mea maʻamau. ʻO ka hāʻawi ʻana i ka pembrolizumab me ka stereotactic body radiation therapy e hana maikaʻi paha i ka mālama ʻana i nā mea maʻi me ka maʻi ʻaʻai Merkel.

Kahi: 246 mau wahi

Ke aʻo pono a me ka palekana o Tisotumab Vedotin no nā mea maʻi me nā tumors paʻa

E hoʻopaʻa kēia hoʻokolohua i ka tisotumab vedotin e ʻike ai inā he lapaʻau maikaʻi ia no kekahi mau tumors paʻa a me nā hopena ʻē aʻe (nā hopena i makemake ʻole ʻia) e kū mai. E hāʻawi ʻia ka lapaʻau i nā mea maʻi i kēlā me kēia ʻekolu pule.

Kahi: 12 mau wahi

PD-1 i nā mea maʻi me ka Advanced Basal Cell Carcinoma ʻO ka mea i ʻike i ka holomua o ka maʻi ma ka Hedgehog Pathway Inhibitor Therapy, a i ʻole he Intolerant o Prior Hedgehog Pathway Inhibitor Therapy

ʻO ka pahuhopu nui ke kuhi i ka nui o ka pane pane (ORR) no ka metastatic Basal Cell Carcinoma (BCC) (hui 1) a no ka BCC holomua kūloko ʻole (hui 2) ke mālama ʻia me REGN2810 ma ke ʻano he monotherapy.

Kahi: 15 mau wahi

Ka Papa II Haʻawina o Tipifarnib i ka Squamous Head a me ka Leʻa Kaʻa me nā HRAS Mutations

ʻImi ʻia ka pae II e noiʻi i ka hana antitumor e pili ana i ka pane pane pahuhopu (ORR) o tipifarnib i nā kumuhana me nā tumors kiʻekiʻe e hāpai ana i ka HRAS mutations a no lākou hoʻi kahi maʻamau curative therapy i loaʻa. Nānā; ʻO cohort 2 (Head & Neck SCC) wale nō a me cohort 3 (Other SCC) e wehe ʻia i kēia manawa

Kahi: 11 mau wahi

ʻO kahi noiʻi Immuno-therapy e noiʻi e noiʻi i ka palekana a me ka pono o Nivolumab, a me Nivolumab Combapy Therapy i nā Tumors e pili ana i ka Virus.

ʻO ke kumu o kēia noi ʻana e nānā i ka palekana a me ka pono o ka nivolumab, a me ka nivolumab hui pū ʻia, e mālama ai i nā mea maʻi i loaʻa i nā tumor e pili ana i ka maʻi virus. Ua ʻike ʻia kekahi mau mea ʻino e pāʻani i ka hana a me ka ulu ʻana o ka tumo. E nānā ana kēia noiʻi i nā hopena o nā lāʻau i hoʻopaʻa ʻia, i nā mea maʻi i loaʻa nā ʻano tumors penei: - Ka maʻi ʻaʻai canal anal-ʻAʻole kākau inoa hou i kēia ʻano tumo - maʻi ʻaʻai cervical - Epstein Barr Virus (EBV) maʻi ʻōpū gastric maikaʻi-ʻAʻole kākau inoa hou i kēia. ʻano tumo - Ka maʻi ʻaʻai ʻo Merkel Cell - Ka maʻi ʻaʻai Penile-ʻAʻole kākau inoa hou i kēia ʻano tumo - Wela a me nā maʻi ʻino ʻele - ʻAʻole kākau inoa hou i kēia ʻano tumo - Ka maʻi ʻaʻai Nasopharyngeal - ʻAʻole kākau inoa hou i kēia ʻano tumo

Kahi: 10 mau wahi

ʻO Pembrolizumab Versus Placebo Ma hope o ke kahakaha ʻana a me ka uila i nā mea e komo pū ana me ka Carcinoma Pūnaewele Kūʻai Kūloko Kūloko Kūloko (MK-3475-630 / KEYNOTE-630)

ʻO kēia kahi noiʻi, makapō makapō, i hoʻopaʻa ʻia e hoʻohālikelike i ka pembrolizumab me kahi placebo i hāʻawi ʻia ma ke ʻano he adjuvant therapy i nā mea e komo pū ana me ka carcinoma cell camoous camous cotile cousse delicado (LA cSCC) i ʻoki ʻia me ka manaʻo curative i hui pū ʻia me radiotherapy. ʻO ke kuhiakau mua ka mea i ʻoi aku ka kiʻekiʻe o ka pembrolizumab ma mua o ka placebo i ka hoʻonui ʻana i ke ola manuahi (RFS).

Kahi: 10 mau wahi

Loiloi ʻia kēia noi ʻana iā KRT-232, kahi Mea Hoʻolaha Molecule Liʻiliʻi Liʻiliʻi o MDM2, no ka hoʻomaʻamaʻa ʻana i nā mea maʻi me (p53WT) Merkel Cell Carcinoma nāna i hōʻole i ka anti-PD-1 / PD-L1 Immunotherapy.

Loiloi ʻia kēia noiʻi ʻana iā KRT-232, kahi mea hoʻopōkole mole liʻiliʻi liʻiliʻi o MDM2, no ka mālama ʻana i nā mea maʻi me Merkel Cell Carcinoma (MCC) i kūleʻa i ka mālama ʻana me hoʻokahi anti-PD-1 a i ʻole anti-PD-L1 immunotherapy. ʻO ka pāpā ʻana iā MDM2 kahi ʻano hana o ka hana i MCC. ʻO kēia haʻawina ʻo Phase 2, Open-Label, Single-Arm Study o KRT-232 i nā mea maʻi me p53 Wild-Type (p53WT) Merkel Cell Carcinoma

Kahi: 11 mau wahi

Ke aʻo ʻana o XmAb®23104 i nā kumuhana me nā Tumors Solid Advanced i wae ʻia (DUET-3)

ʻO kēia kahi pae 1, nā mahele lāʻau he nui, e piʻi nei i ka hoʻonui ʻana o ka lāʻau e wehewehe ai i ka MTD / RD a me ka regimen o XmAb23104, e wehewehe i ka palekana a me ka hoʻomanawanui ʻana, e nānā iā PK a me ka immunogenicity, a me ka loiloi mua i ka hana anti-tumor o XmAb23104 i nā kumuhana me ke koho ʻia. nā tumors paʻa holomua.

Kahi: 9 mau wahi

ʻO Adjuvant Avelumab ma Merkel Cell Cancer

Ke aʻo nei kēia pae III i ka hoʻokolohua ʻana i ka maikaʻi o ka hana avelumab i ka mālama ʻana i nā mea maʻi me ka maʻi ʻaʻai Merkel i hele i nā lymph node a ua hana ʻia me kahi me ka ʻole o radiation radiation. Monoclonal antibodies, e like me avelumab, hiki ke hoʻonāukiuki i ka ʻōnaehana pale pale a hoʻopilikia i ka hiki i nā pūpū tumora ke ulu a pālahalaha.

Kahi: 10 mau wahi

QUILT-3.055: Ke aʻo ʻana o ALT-803 i ka hui pū ʻana me ka PD-1 / PD-L1 Checkpoint Inhibitor i nā maʻi me ka maʻi ʻaʻai nui.

ʻO kēia kahi Phase IIb, ka lima hoʻokahi, ka multicohort, ke aʻo inoa multicenter hāmama o ALT-803 i hui pū ʻia me ka mea kāohi i ʻae ʻia e ka FDA i hōʻoia ʻia e PD-1 / PD-L1 i nā mea maʻi me nā maʻi maʻi holomua i holomua ma hope o ka pane mua ʻana i ka mālama ʻana me PD-1 / PD-L1 checkpoint inhibitor therapy. E loaʻa i nā poʻe maʻi āpau ka mālama ʻana o ka PD-1 / PD-L1 checkpoint inhibitor a me ALT-803 a 16 mau pōʻaiapuni. ʻEono mau pule ke lōʻihi o kēlā me kēia pōʻaiapuni. E loaʻa i nā mea maʻi āpau ka ALT-803 hoʻokahi manawa i kēlā me kēia 3 mau pule. E loaʻa pū nā mea maʻi i ka mea nāna i hoʻopaʻa i ka checkpoint like i loaʻa iā lākou i ka wā o kā lākou hana mua. E kū ana ka loiloi radiologic ma ka hopena o kēlā me kēia pōʻaiapuni. E hoʻomau ka hoʻomaʻamaʻa a hiki i 2 mau makahiki, a i ʻole a ʻike ka mea hoʻomanawanui i hōʻoia i ka maʻi holomua a i ʻole ka ʻino kūpono ʻole, e huki i ka ʻae, aiʻole inā manaʻo ka mea noiʻi ʻaʻole ia i ka pono o ka mea maʻi e hoʻomau i ka lāʻau. E ukali ʻia nā mea maʻi no ka holomua ʻana o ka maʻi, post-therapies, a me ke ola ʻana ma o 24 mau mahina i hala i ka lawelawe ʻana o ka lāʻau mua o ka lāʻau noiʻi.

Kahi: 9 mau wahi

Palekana, Tolerability, Immunogenicity, a me Antitumor Hana o GEN-009 Adjuvanted Vaccine

I loko o kēia noi ʻana, ke loiloi nei ʻo Genocea i kahi lāʻau lapaʻau adjuvanted pilikino e pili ana iā ia iho, GEN-009, ke hoʻomohala ʻia nei no ka mālama ʻana i nā maʻi me nā tumors paʻa. E hoʻohana ʻia kahi pono pono e Genocea, i kapa ʻia ʻo ATLAS ™ (Antigen Lead Acqu acquisition System) e hoʻomaopopo ai i nā neoantigens i kēlā me kēia tumo hoʻomanawanui i ʻike ʻia e kā lākou CD4 a me / a i ʻole CD8 T. E hoʻokomo ʻia nā neoantigens i ʻike ʻia me ATLAS i loko o ka lāʻau āpau pilikino o ka mea maʻi ma ke ʻano he peptides lōʻihi synthetic (SLPs).

Kahi: 9 mau wahi

Ke aʻo ʻana o NKTR-262 i ka hui pū ʻana me NKTR-214 a me NKTR-214 Plus Nivolumab i nā mea maʻi me kahi kūloko kūloko a i ʻole nā ​​Metastatic Solid Tumor Malignancies

E loaʻa i nā mea maʻi nā intra-tumoral (IT) NKTR-262 i nā holo o ka hoʻomaʻamaʻa 3-wiki. Ma ka ʻāpana Hoʻonui 1 ka piʻi ʻana o ka hoʻokolokolo, e hui pū ʻia ʻo NKTR-262 me ka lawelawe ʻōnaehana o bempegaldesleukin. Ma hope o ka hoʻoholo ʻana o ka paukū pae 2 i koi ʻia (RP2D) o NKTR-262, ma waena o 6 a me 12 mau mea maʻi i kākau inoa ʻia ma ka RP2D e hōʻike hou aku ai i ka ʻike palekana a me ka hoʻomanawanui ʻana o ka hoʻohui o NKTR 262 a me bempegaldesleukin (pālua) a i ʻole NKTR 262 hoʻohui bempegaldesleukin me ka hui pū me nivolumab (triplet) ma Cohorts A a me B. I ka mahele hoʻonui hoʻonui 2 mahele, e mālama ʻia nā mea maʻi me ka pālua a i ʻole ka kolu i ka hoʻonohonoho hou ʻia / refactory a me nā laina o ka therapy.

Kahi: 14 mau wahi

ʻO kahi hoʻokolohua kaulike ʻole o Pembrolizumab & Radiotherapy Versus Radiotherapy i ka High-Risk Soft Tissue Sarcoma o ka Extremity

ʻO kēia kahi lepili hāmama, kahi papahana multi-institution II i hoʻopaʻa ʻia i ka hoʻohālikelike ʻana i ka radiotherapy neoadjuvant ukali ʻia e ke kaha lāʻau neoadjuvant pembrolizumab me ka radiotherapy like, a ukali ʻia e ka ʻoki kino a me adjuvant pembrolizumab. ʻO ka lōʻihi o ka manawa o pembrolizumab e lilo i hoʻokahi makahiki i ka lima hoʻokolohua.

Kahi: 10 mau wahi

ʻO Proton Beam a i ʻole Photon-Base Intensity-Modulated Radiation Therapy i ka mālama ʻana i nā mea maʻi me ka maʻi ʻaʻai Salivary Gland, Ka maʻi ʻaʻai, a me Melanoma.

Ke aʻo nei kēia mahele II i ka hopena o ka proton beam a i ʻole photon-based intensity-modulated radiation therapy i ka mālama ʻana i nā mea maʻi me ka maʻi ʻaʻai salivary gland, cancer cancer, a melanoma paha. Hoʻohana ka radiation radiation Proton i nā mea liʻiliʻi i hoʻouku ʻia e lawe pololei i ka radiation i ka tumo a hoʻoliʻiliʻi paha ka hōʻino ʻana i nā mea maʻamau. Hoʻohana-pinepine ʻia a i ʻole photon beam radiation radiation e hoʻohana i nā kaola x-ray kiʻekiʻe-ikehu i hoʻohālikelike ʻia e mālama ai i ka tumo a hoʻoliʻiliʻi paha i ka hōʻino ʻana i nā mea maʻamau. ʻAʻole i ʻike ʻia inā ʻoi aku ka maikaʻi o ka proton radiation radiation therapy ma mua o ka photon-based intensity-modulated radiation therapy i ka mālama ʻana i nā mea maʻi me ka maʻi ʻaʻai salivary gland, cancer cancer, a melanoma paha.

Kahi: 8 mau wahi

ʻO ka uila ʻili uila o Brachytherapy i ka mālama ʻana i nā mea maʻi ʻelemakule me ka New Basque Cell Basal Cell a i ʻole ka Squamous Cell Skin Cancer

Ke aʻo nei kēia hoʻokolohua hoʻokolohua hoʻokolohua i ka maikaʻi o ka hana ʻana o ka ʻili uila brachytherapy (ESSB) i ka mālama ʻana i nā mea maʻi ʻoi aku ka maʻi me ke kanulau basal cell i hōʻike mua ʻia a i ʻole ka maʻi ʻaʻai squamous. ʻO ka ESSB kahi ʻano o ka radiation therapy e hoʻohana ai i nā ʻili ʻili e hoʻonoho i nā kumu uila uila e mālama ai i ka maʻi ʻaʻai. Poepoe nā mea noi ʻili i ʻili, paheʻe i hoʻopili ʻia i ka mīkini hoʻomaʻemaʻe radiation, a hāʻawi i ka radiation no ka mālama ʻana. E ʻae ʻo ESSB i ka tumo e mālama ʻia ʻoiai e ʻeha ʻole nā ​​kumu ola olakino i ka radiation.

Kahi: 8 mau wahi

ʻO ka Therapy Radiation Body Stereotactic i ka mālama ʻana i nā mea maʻi me ka maʻi ʻaʻai Metastatic me ka holomua o ka holomua ma nā Inhibitors Immune Checkpoint

Ke aʻo nei kēia mahele II i ke ʻano o ka hana ʻana o ka stereotactic body radiation therapy i ka mālama ʻana i nā mea maʻi me ka maʻi ʻaʻai i pāhola ʻia i nā wahi ʻē aʻe o ke kino me ka holomua o ka holomua ʻoiai ka pale pale pale pale pale. Hoʻohana ka radiation radiation body Stereotactic i nā pono hana kūikawā e hoʻonohonoho i kahi mea maʻi a hāʻawi i ka radiation i nā tumors me ke kiʻekiʻe kiʻekiʻe. Hiki i kēia hana ke luku i nā hunaola puʻupuʻu me ka liʻiliʻi o nā mahele ma kahi o ka manawa pōkole a hōʻemi i ka hōʻino ʻana i nā mea maʻamau.

Kahi: 7 mau wahi

ʻO Cabozantinib S-malate a me Cetuximab i ka mālama ʻana i nā mea maʻi me ka Metastatic Head a me ka Leʻa Cell Squamous Cell

Ke aʻo nei kēia mahele hoʻokolohua i nā hopena a me ka hopena maikaʻi loa o cabozantinib S-malate a ke hāʻawi pū ʻia me cetuximab i ka mālama ʻana i nā mea maʻi me ke kanesa a me ka ʻāʻī puʻupuʻu puʻupuʻu i pāhola ʻia i nā wahi ʻē aʻe o ke kino. Hiki i ka Cabozantinib S-malate ke hoʻolohi i ka ulu ʻana o nā hunaola maʻi ʻaʻai ma ke ʻoki ʻana i ke koko e pono ai ka maʻi ʻaʻai e ola a ulu. Immunotherapy me nā monoclonal antibodies, e like me cetuximab, hiki ke hoʻohuli i nā loli i ka ʻōnaehana pale o ke kino a hoʻopilikia paha i ka hiki ke ulu a pālahalaha nā pūnaewele tumora. ʻOi aku ka maikaʻi o ka hāʻawi ʻana iā cabozantinib S-malate a me cetuximab i ka mālama ʻana i nā mea maʻi me ka maʻi ʻaʻai poʻo a me ka ʻāʻī.

Kahi: 7 mau wahi

Ka palekana, ka pono mua a me ka PK o Isatuximab (SAR650984) Hoʻokahi a i ʻole me ka hui pū ʻana me Atezolizumab i nā mea maʻi me nā maʻi maʻi holomua.

N Object Pahuhopu: - Phase1: E wehewehe i ka palekana a me ke ahonui o ka isatuximab me ka hui pu me atezolizumab i ka poʻe e komo pū ana me ka carcinoma hepatocellular (HCC), ka platinum-refactory recurrent / metastatic squamous cell carcinoma o ke poʻo a me ka ʻāʻī (SCCHN), kūpaʻa ʻole / refactory epithelial ovarian cancer (EOC), a i ʻole glioblastoma multiforme (GBM) hou, a no ka hoʻoholo ʻana i ka paukū Phase 2 i koi ʻia (RP2D). - Phase2: e nānā i ka pane pane (RR) o isatuximab me ka hui pū ʻana me atezolizumab i nā mea komo me HCC a i ʻole SCCHN a i ʻole EOC. - Phase2: e nānā i ka holomua ola manuahi holomua ma 6 mau mahina (PFS-6) o isatuximab i hui pū ʻia me atezolizumab, a i ʻole ma ke ʻano he agena hoʻokahi i nā mea komo me GBM. Nā Pahuhopu Nui: - E loiloi i ka ʻike palekana o ka monotherapy isatuximab (GBM wale nō), aiʻole i ka hui pū ʻia me atezolizumab i ka pae 2. - E loiloi i ka immunogenicity o isatuximab a me atezolizumab. - E hoʻokalakupua i ka profile pharmacokinetic (PK) o isatuximab hoʻokahi agena (GBM wale nō) a me atezolizumab me ka isatuximab. - E nānā i ka hopena holoʻokoʻa o ka isatuximab i hui pū ʻia me atezolizumab, a i ʻole agena hoʻokahi (GBM wale nō).

Kahi: 7 mau wahi

Ke aʻo ʻana o INCMGA00012 i ka Metastatic Merkel Cell Carcinoma (POD1UM-201)

ʻO ke kumu o kēia noi ʻana e loiloi i ka hana olakino a me ka palekana o INCMGA00012 i nā mea komo me ka carcinoma Merkel cell carcinoma (MCC) holomua / metastatic.

Kahi: 8 mau wahi

ʻO Lenvatinib Mesylate a me Cetuximab i ka mālama ʻana i nā mea maʻi me ke poʻo hou a Metastatic poʻo a me ka ʻāʻī puʻupuʻu puʻupuʻu puʻupuʻu a i ʻole Cutaneous Squamous Cell Carcinoma

Ke aʻo nei kēia hoʻokolohua I / Ib i ka mahele lāʻau maikaʻi loa a me nā hopena ʻē aʻe o ka lenvatinib mesylate a me ka cetuximab i ka mālama ʻana i nā mea maʻi me ke poʻo a me ka ʻāʻī pūnaewele cell caromaoma a i ʻole cutaneous squamous cell carcinoma i hoʻi mai (recurrent) a hoʻolaha ʻia i nā wahi ʻē aʻe o ke kino (metastatic ). Hiki iā Lenvatinib mesylate ke hoʻōki i ka ulu ʻana o nā hunaola tumola ma ke kāpae ʻana i kekahi o nā ʻenema e pono ai no ka ulu ʻana o ka cell. Hoʻopilikia paha nā monoclonal antibodies, e like me cetuximab, me ka hiki ke ulu a pālahalaha nā pūhaka tumora. ʻOi aku ka maikaʻi o ka hāʻawi ʻana i ka lenvatinib mesylate a me ka cetuximab i ka mālama ʻana i nā mea maʻi me ke poʻo a me ka ʻāʻī squamous cell carcinoma a i ʻole ke cinaneus squamous cell carcinoma.

Kahi: 7 mau wahi

PEN-221 ma Somatostatin Receptor 2 e hōʻike nei i nā ʻōpala holomua me Neuroendocrine a me nā liʻi liʻiliʻi liʻiliʻi liʻiliʻi Protocol PEN-221-001 kahi lepili wehe, multicenter Phase 1 / 2a kahi loiloi iā PEN-221 i nā mea maʻi me SSTR2 e hōʻike ana i ka gastroenteropancreatic holomua (GEP) a i ʻole. lung a thymus a i ʻole nā ​​tumo neuroendocrine ʻē aʻe a i ʻole ke kanesa maʻi ʻaʻa liʻiliʻi liʻiliʻi a i ʻole ke neuroendocrine cell cancer o ka māmā.

Kahi: 7 mau wahi

1 2 3 4 5 Aʻe> Ke Kula Kaiapuni ʻAmelika